| A Phase Ⅰb/Ⅱ Clinical Study of Clifutinib Besylate Combined With Chemotherapy in the Treatment of Newly Diagnosed AML (NCT05133882) | Sunshine Lake Pharma Co., Ltd. | 2022-10-31 |
| A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus (NCT05465707) | Keymed Biosciences Co.Ltd | 2022-10-30 |
| Photobiomodulation in Post Menopause Genitourinary Syndrome (NCT05557799) | University of Nove de Julho | 2022-10-30 |
| Effects of Anesthetic Infusion on the Amplitude of Motor Evoked Potential in Pediatrics Undergoing Tethered Spinal Cord Surgeries (NCT05591001) | Cairo University | 2022-10-30 |
| Study to Evaluate Pharmacokinetics, Safety & Tolerability of 101-PGC-005 in Healthy, Adult, Human Subjects (NCT05619770) | 101 Therapeutics | 2022-10-29 |
| Targeted Fluorescence Imaging in AMD (NCT05262244) | University Medical Center Groningen | 2022-10-28 |
| Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia (NCT05396859) | OHSU Knight Cancer Institute | 2022-10-28 |
| A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer (NCT05394259) | M.D. Anderson Cancer Center | 2022-10-28 |
| Felodipine Controlled Release Tablets and Felodipine Sustained Release Tablets in Healthy Subjects Under Fasting State Comparative Pharmacokinetic Study (NCT05614037) | Overseas Pharmaceuticals, Ltd. | 2022-10-28 |
| Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 100 mg /1000 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions. (NCT06124560) | Galenicum Health | 2022-10-28 |
| PsilOCD: A Pharmacological-Challenge Feasibility Study (NCT06258031) | Imperial College London | 2022-10-28 |
| Paresthesia-free Peripheral Nerve Field Stimulation for Trigeminal Neuralgia (FreeST Trial) (NCT05615714) | University Health Network, Toronto | 2022-10-28 |
| Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor (NCT05383703) | Moon (Guangzhou) Biotechnology Co., Ltd. | 2022-10-28 |
| ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression (NCT05434156) | Eleusis Therapeutics | 2022-10-27 |
| An Exploratory Single-arm Study: PD-1 With Recombinant Human Adenovirus Type 5 Injection for Malignant Melanomas (NCT05928962) | Fujian Cancer Hospital | 2022-10-27 |
| A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine (NCT07465731) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2022-10-27 |
| SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN) (NCT05435742) | Sonnet BioTherapeutics | 2022-10-27 |
| A Study of NT 201 in the Treatment of Enlarged Pores and Excessive Sebum Production in the Face (NCT05784363) | Merz North America, Inc. | 2022-10-27 |
| A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet (NCT05564208) | Ipsen | 2022-10-27 |
| A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (NCT05458219) | Innovent Biologics (Suzhou) Co. Ltd. | 2022-10-26 |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (NCT05169515) | Hoffmann-La Roche | 2022-10-26 |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (NCT05536141) | Arcus Biosciences, Inc. | 2022-10-26 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers (NCT05544929) | Novartis Pharmaceuticals | 2022-10-26 |
| DCBY02 as a Monotherapy in Patients With Advanced or Metastatic Solid Tumors (NCT05496595) | DynamiCure Biotechnology | 2022-10-26 |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis (NCT05451771) | Columbia University | 2022-10-26 |
| Study of Novel Antiretrovirals in Participants With HIV-1 (NCT05585307) | Gilead Sciences | 2022-10-26 |
| BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors (NCT05120271) | Sotio Biotech Inc. | 2022-10-26 |
| A Study of XSTEM-VLU in Patients With Difficult-to-heal Venous Leg Ulcers (NCT05549609) | Xintela AB | 2022-10-26 |
| Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors (NCT05608148) | Kyushu University | 2022-10-26 |
| A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma (NCT05417932) | SCG Cell Therapy Pte. Ltd. | 2022-10-26 |
| Clinical Trial to Evaluate Safety and Efficiency of Mesenchymal Stem Cell in Patients With Hidradenitis Suppurativa (NCT05934825) | Andalusian Network for Design and Translation of Advanced Therapies | 2022-10-26 |
| Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects (NCT05812404) | Daewoong Pharmaceutical Co. LTD. | 2022-10-26 |
| To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR Mutation (NCT05555212) | Qilu Pharmaceutical Co., Ltd. | 2022-10-25 |
| CD5 CAR-T Therapy for Refractory/Relapsed CD5+ T-cell Acute Lymphoblastic Leukemia (NCT05596266) | Xuanwu Hospital, Beijing | 2022-10-25 |
| A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food (NCT05347004) | Boehringer Ingelheim | 2022-10-25 |
| Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors (NCT05620862) | Sun Yat-sen University | 2022-10-25 |
| A Study to Evaluate the PK Similarity of AK104 in Healthy Chinese Male Subjects (NCT05559554) | Akeso | 2022-10-25 |
| A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related (NCT06617000) | SCG Cell Therapy Pte. Ltd. | 2022-10-25 |
| A Study of MK-0616 in Healthy Adult Participants (MK-0616-009) (NCT06592339) | Merck Sharp & Dohme LLC | 2022-10-25 |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (NCT05208762) | Seagen, a wholly owned subsidiary of Pfizer | 2022-10-25 |
| A Study of TNM001 in Chinese Healthy Preterm and Term Infants (NCT05630573) | Zhuhai Trinomab Pharmaceutical Co., Ltd. | 2022-10-25 |
| A Study of LY3437943 in Chinese Participants With Obesity Or Overweight (NCT05548231) | Eli Lilly and Company | 2022-10-24 |
| A Trial to Learn if REGN7999 is Safe and Well Tolerated, and How it Works in the Body of Healthy Participants (NCT05481333) | Regeneron Pharmaceuticals | 2022-10-24 |
| Comparative Bioavailability Study Between Etoricoxib / Betamethasone Administered Individually or in Combination (NCT07454369) | Laboratorios Silanes S.A. de C.V. | 2022-10-24 |
| Clinical Trial to Evaluate if the Laparoscopic Administration of Cells Derived From the Fatty Tissue Can Improve the Inflammatory Stenosis in Patient With Crohn's Disease (NCT05521672) | Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz | 2022-10-24 |
| Effects of SERT Inhibition on the Subjective Response to LSD in Healthy Subjects (NCT05175430) | University Hospital, Basel, Switzerland | 2022-10-24 |
| Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia (NCT04527224) | Nature Cell Co. Ltd. | 2022-10-24 |
| Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors (NCT05586321) | Genmab | 2022-10-24 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation (NCT05358249) | Novartis Pharmaceuticals | 2022-10-24 |
| Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD 371 in Healthy Subjects (NCT05544214) | Chong Kun Dang Pharmaceutical | 2022-10-21 |
| A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer. (NCT05497778) | M.D. Anderson Cancer Center | 2022-10-21 |
| Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer (NCT05425862) | Peter MacCallum Cancer Centre, Australia | 2022-10-21 |
| A Study to Investigate the Interaction of BMS-986322 and a Combined Oral Hormonal Contraceptive (Ethinyl Estradiol [EE]/Norethindrone [NET]) in Healthy Female Participants (NCT05579574) | Bristol-Myers Squibb | 2022-10-21 |
| Single-Ascending Dose Study of JK07 in Subjects With HFpEF (NCT05322616) | Salubris Biotherapeutics Inc | 2022-10-21 |
| A Study of FB2001 for Inhalation in Healthy Chinese Adults (NCT05583812) | Frontier Biotechnologies Inc. | 2022-10-21 |
| HEC169096 in Participants With Advanced Solid Tumors (NCT05451602) | Sunshine Lake Pharma Co., Ltd. | 2022-10-21 |
| Study to Evaluate Safety & Usability of a New Formulation for Male Androgenetic Alopecia (NCT05611593) | Follicle Pharma Ltd | 2022-10-20 |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma (NCT05259839) | AbbVie | 2022-10-20 |
| Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors. (NCT05547321) | Oncomatryx Biopharma S.L. | 2022-10-20 |
| Effect of High Intensity Laser on Hemiplegic Shoulder Dysfunction (NCT05595720) | Deraya University | 2022-10-20 |
| Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects (NCT05503511) | NeuroPro Therapeutics, Inc. | 2022-10-20 |
| Post-transplant Flotetuzumab for AML (NCT05506956) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2022-10-20 |
| Turmeric Gel as Alternative Non-vital Pulpotomy Medicament in Primary Teeth (NCT05801354) | University of Health Sciences Lahore | 2022-10-20 |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Pomalidomide and Dexamethasone in Patients With Relapsed/ Refractory Multiple Myeloma Previously Treated With One Line Therapy Who Are Lenalidomide Refractory (NCT05581875) | Hellenic Society of Hematology | 2022-10-20 |
| The Effects of Glucagon on Hepatic Metabolism (NCT05500586) | Adrian Vella | 2022-10-20 |
| Allium Sativum Oil and Turmeric Gel as Alternative Non-vital Pulpotomy Medicaments in Primary Teeth. (NCT05819970) | University of Health Sciences Lahore | 2022-10-20 |
| Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer (NCT05869123) | Peking Union Medical College Hospital | 2022-10-20 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors (NCT05581004) | Genentech, Inc. | 2022-10-20 |
| Allium Sativum Oil as Alternative Non-vital Pulpotomy Medicament in Primary Teeth (NCT05801367) | University of Health Sciences Lahore | 2022-10-20 |
| A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants (NCT05567510) | Bristol-Myers Squibb | 2022-10-20 |
| Food Effect Study on the Pharmacokinetics of VC004 Capsules in Healthy Adult Subjects (NCT05528120) | Jiangsu vcare pharmaceutical technology co., LTD | 2022-10-20 |
| Silodosin in Management of Lower Ureteral Stones (NCT06381206) | Syrian Private University | 2022-10-20 |
| SHP2 Inhibitor BBP-398 in Combination With Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer With a KRAS Mutation (NCT05375084) | Navire Pharma Inc., a BridgeBio company | 2022-10-20 |
| E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma (NCT05388877) | Mayo Clinic | 2022-10-20 |
| A Study to Evaluate the Distribution of Botulinum Neurotoxin Type A Administered as Intradermal Injections, Comparing Different Doses, Concentrations, and Delivery Methods (NCT05585398) | Merz Pharmaceuticals GmbH | 2022-10-19 |
| A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent Glioblastoma (NCT05324501) | Biodexa Pharmaceuticals | 2022-10-19 |
| U87 CART in Treatment of Advanced Solid Tumor (NCT05605197) | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 2022-10-19 |
| Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants (NCT05581823) | Cerevel Therapeutics, LLC | 2022-10-19 |
| Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma (NCT05391750) | Emory University | 2022-10-19 |
| Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors (NCT05539157) | Immorna Biotherapeutics, Inc. | 2022-10-18 |
| A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma (NCT05372354) | Bristol-Myers Squibb | 2022-10-18 |
| Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects (NCT05619536) | Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2022-10-18 |
| Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers (NCT05688085) | Handok Inc. | 2022-10-18 |
| Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19 (NCT05582603) | Universidad Antonio de Nebrija | 2022-10-18 |
| Safety and Tolerability, and PK of Sibeprenlimab in Chinese Healthy Subject (NCT07105124) | Otsuka Beijing Research Institute | 2022-10-18 |
| Study to Assess Adverse Events and Compare How Two Subcutaneous ABBV-154 Injection Formulations Move Through the Body of Adult Healthy Participants (NCT05556226) | AbbVie | 2022-10-18 |
| A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the Blood (NCT05467475) | Boehringer Ingelheim | 2022-10-18 |
| A Study of Ponesimod in Healthy Adult Participants (NCT05552196) | Janssen Pharmaceutica N.V., Belgium | 2022-10-18 |
| Phase I Study of the BBP-398 in Patients With Advance Solid Tumors (NCT05621525) | LianBio LLC | 2022-10-18 |
| Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia (NCT04255147) | Ottawa Hospital Research Institute | 2022-10-17 |
| A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (NCT05535244) | Hoffmann-La Roche | 2022-10-17 |
| Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC. (NCT06344715) | SL VAXiGEN | 2022-10-17 |
| Icodextrin Study to Test Short-Term Safety, Tolerability and Preliminary Efficacy of Sodium-Free Solution in PD Patients (NCT05185999) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2022-10-17 |
| Study to Evaluate Electrocardiographic Effects of Therapeutic & Supratherapeutic Doses of Cytisinicline in Healthy Smokers (NCT05566288) | Achieve Life Sciences | 2022-10-17 |
| Study of AT-527 in Subjects With Normal and Impaired Renal Function (NCT05618314) | Atea Pharmaceuticals, Inc. | 2022-10-17 |
| A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People (NCT05580003) | Pfizer | 2022-10-17 |
| Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer (NCT05620134) | Salubris Biotherapeutics Inc | 2022-10-17 |
| A Study to Determine the Absolute Bioavailability and the Absorption, Metabolism, and Elimination Properties of Carbon-14 (14C)E7386 in Healthy Male Participants (NCT05607537) | Eisai Limited | 2022-10-17 |
| HCW9218 for Advanced Pancreatic Cancer (NCT05304936) | ImmunityBio, Inc. | 2022-10-17 |
| A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants (NCT05654181) | Pfizer | 2022-10-17 |